Alpha Tau Medical Ltd

Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumors. Alpha DaRT works by intratumoral delivery of radium-224 impregnated sources, which release short-lived alpha-emitting atoms that disperse within the tumor to destroy cancer cells while aiming to spare surrounding healthy tissue. Founded in 2016, the technology was originally developed at Tel Aviv University. The company is publicly traded on NASDAQ under the tickers DRTS and DRTSW. Alpha Tau is currently pre-commercial in most markets, with active clinical trials across multiple solid tumor indications including recurrent glioblastoma, cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer. The company received PMDA marketing approval in Japan for Alpha DaRT in unresectable locally advanced or locally recurrent head and neck cancer and has received FDA Breakthrough Device Designation for recurrent cutaneous squamous cell carcinoma. It is conducting clinical trials in the United States, Canada, Israel, France, and Italy. Updated May 18, 2026